Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ATM | Q13315 | 1/20 | 0.36 |
| ▸ | PPM1D | O15297 | 1/20 | 0.33 |
| ▸ | VHL | P40337 | 1/20 | 0.30 |
| ▸ | ELOC | Q15369 | 1/20 | 0.30 |
| ▸ | ELOB | Q15370 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15203438 | 1.00 | ATM (0.36) | ATMPPM1DVHLELOCELOB | |
| SCHEMBL30345061 | 1.00 | ATM (0.36) | ATMPPM1DVHLELOCELOB | |
| SCHEMBL3477748 | 1.00 | ATM (0.36) | ATMPPM1DVHLELOCELOB | |
| SCHEMBL4330399 | 1.00 | ATM (0.36) | ATMPPM1DVHLELOCELOB | |
| SCHEMBL30729549 | 1.00 | ATM (0.36) | ATMPPM1DVHLELOCELOB | |
| SCHEMBL28776789 | 0.91 | ATM (0.36) | ATMPPM1DVHLELOCELOB | |
| SCHEMBL5633357 | 0.90 | ATM (0.49) | ATMPPM1DVHLELOCELOB | |
| SCHEMBL22367414 | 0.88 | PPM1D (0.34) | ATMPPM1D | |
| SCHEMBL30104016 | 0.87 | TSHR (0.37) | ATMPPM1D | |
| SCHEMBL1002756 | 0.87 | PPM1D (0.32) | PPM1D |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-117396474-A | Plasma kallikrein inhibitors | 武田药品工业株式会社 | 2024-01-12 | — | — | CN | disclosed |
| US-7659279-B2 | 2-{(2S)-2-[({4-[3-Chloro-4-fluoroanilino]-7-methoxyquinazolin-5-yl}oxy)methyl]pyrrolidin-1-yl}-2-oxoethanol; epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors; breast, colorectal and head and neck cancer | ASTRAZENECA AB (SE) | 2010-02-09 | — | — | US | disclosed |
| US-20090264431-A1 | NOVEL CATHEPSIN C INHIBITORS AND THEIR USE | GLAXO GROUP LIMITED (GB) | 2009-10-22 | — | — | US | disclosed |
| WO-2009026197-A1 | NOVEL CATHEPSIN C INHIBITORS AND THEIR USE | GLAXO GROUP LIMITED (GB) | 2009-02-26 | — | — | WO | disclosed |
| EP-1622620-B1 | QUINAZOLINE DERIVATIVES AND THEIR USE IN THE TREATMENT OF CANCER | ASTRAZENECA AB (SE) | 2008-02-20 | — | — | EP | disclosed |
| US-20060211714-A1 | Quinazoline derivatives and their use in the treatment of cancer | ASTRAZENECA AB (SE) | 2006-09-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090264431-A1 | NOVEL CATHEPSIN C INHIBITORS AND THEIR USE | CTSB, CTSS, CTSF | ATM 4495/4885PPM1D 4382/4885VHL 1973/4885 |
| US-20060211714-A1 | Quinazoline derivatives and their use in the treatment of cancer | EGFR, ERBB2, ERBB4 | ATM 450/4885PPM1D 675/4885VHL 1078/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.